Piramal Pharma Q1 FY2027 EBITDA Surges 72% to Rs 285 Crore; FY27 Capex of Rs 1,000 Crore Reaffirmed

The Quick Take

• Piramal Pharma reported Q1 FY2027 EBITDA of Rs 285 crore, a 72% increase year-over-year, driven by strong performance across its contract development and manufacturing (CDMO) and India consumer healthcare businesses
• Management reaffirmed its FY2027 capital expenditure plan of up to Rs 1,000 crore, signaling continued confidence in capacity expansion investments to service growing CDMO demand from global pharmaceutical companies
• The result validates Piramal Pharma's dual strategy of building a high-margin CDMO business while maintaining a profitable domestic consumer healthcare portfolio, with both segments contributing positively in Q1

Piramal Pharma's Q1 FY2027 EBITDA of Rs 285 crore — up 72% year-over-year — marks a significant inflection in profitability after multiple quarters of margin investment associated with capacity expansion and integration activities. The CDMO business, which provides contract manufacturing services for small molecule APIs, complex injectables, and solid dosage forms to global innovator and generic pharmaceutical companies, was the primary driver of the improvement. CDMO businesses benefit from high operating leverage once facilities are fully qualified and operational: incremental revenue from new batches falls to EBITDA at high margin rates once fixed costs are covered.

The capex commitment of Rs 1,000 crore for FY2027 represents sustained investment in new manufacturing capacities at Piramal's facilities in India and North America. The company's strategy is to build specialized manufacturing capabilities — particularly in complex drug delivery systems, peptides, and specialized sterile injectables — where technical barriers protect margins and switching costs keep customers sticky across product lifecycle. Global pharmaceutical companies' increasing preference for outsourcing manufacturing of complex molecules plays directly to Piramal's investment thesis, as the CDMO market for complex modalities is growing faster than the broader pharmaceutical manufacturing outsourcing market.

India consumer healthcare, Piramal's OTC brand portfolio, also contributed positively, with summer health products and branded pain management contributing seasonal strength. The combination of CDMO margin expansion and consumer healthcare seasonality created a favorable Q1 comparison. The forward watch items are Q2 EBITDA trajectory — whether the 72% growth rate reflects sustainable operating leverage or seasonal factors — CDMO order intake for late FY2027 manufacturing slots, and the pace of capex spending relative to the Rs 1,000 crore annual budget. Any capacity commissioning milestone announcements would be positive catalysts for the stock's forward earnings estimate trajectory.

Synthesized from 1 source.